PRIMAVERA

Start Date

1.11.2021

Duration

60 months

placeholder.jpg
placeholder_edited.jpg

Title: PrIMAVeRa  - Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance


Design: Descriptive/Analytical


Primary Objectives: The goal of PrIMAVeRa is to develop comprehensive mathematical models to predict the impact of vaccines and mAbs on the reduction of AMR, thereby enabling decision-makers to prioritise the most promising new vaccines and mAbs.

A sustainability plan will also be designed by the project partners with the goal to ensure long-term access to the project results, including models, beyond the duration of the PrIMAVeRa project.

The following main goals will be addressed in an integrated manner:

· Assessment of the availability and quality of published data and existing mathematical models of AMR;

· Setting up a comprehensive epidemiological repository;

· Development of improved mathematical models of AMR including cost-effectiveness analyses (CEA);

Establishment of a plan for evaluation


Interested in a collaboration? Contact: Fabiana Arieti (fabiana.arieti@univr.it), Maria Diletta Pezzani (mariadiletta.pezzani@univr.it)

Partners

Ares Genetics GmbH, (AT)
Danmarks Tekniske Universitet, (DK)
Eberhard Karls Universität Tübingen, (DE)
European Vaccine Initiative (EVI), (DE)
GlaxoSmithKline Biologicals SA (GSK), (BE)
Hospital of Lithuanian University of Health Sciences Kauno Klinikos, (LT)
Institut Pasteur, (FR)
Institute of Health Carlos III, (ES)
Janssen Vaccines & Prevention B.V., (NL)
Life Science Network gGmbH, (DE)
Pasteur Institute of Russia, (RU)
Pfizer, (UK)
Public Health England, (UK)
Servicio Andaluz de Salud, (ES)
Université Grenoble Alpes, (FR)
University Medical Center Utrecht (UMC Utrecht), (NL)
University of Geneva, (CH)
University of Oxford, (UK)

ID-CARE

Evelina Tacconelli

Ruth Davis

Maria Diletta Pezzani

Fabiana Arieti